STK11 and cancer: Importantly, LKB1 loss has been shown to promote cancer progression and increase metastatic potential in the genetically engineered mouse models of lung cancer, melanoma, pancreatic cancer, and endometrial cancer (Hermanova et al., 2020; Ji et al., 2007; Liu et al., 2012; Peña et al., 2015).